← The record

Emtricitabine + Tenofovir Alafenamide

Recommended · restricted Infectious diseaseAuthority Required

Treatment of human immunodeficiency virus (HIV) infection in treatment-naïve and treatment-experienced patients, administered in combination with other antiretroviral agents.

1
Submissions
1 resub
2016–16
On the record
ICER range
Cost-min
Cost basis

Access path

1 submission · public record
  1. Nov 2016
    Recommended · restricted

    vs Truvada®

  2. PBS listing · Authority Required
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
4.1 The PBAC recommended the listing of emtricitabine + tenofovir alafenamide as a Section 100 (community access): Authority Required (STREAMLINED) listing for treatment-naïve and treatment-experienced patients with human immunodeficiency virus (HIV) on a cost-minimisation basis to Truvada®.PSD · Nov 2016
4.2 The PBAC noted the evidence presented by the sponsor that indicated tenofovir alafenamide and tenofovir disoproxil fumarate had differences in relation to dose, plasma stability, and metabolism. On this basis, the PBAC considered that tenofovir alafenamide should be considered different drug to tenofovir for the purposes of section 85(2) of the Act.PSD · Nov 2016

Cost-effectiveness

Cost-minimisation analysis conducted; no incremental ICER calculated

Cost-effectiveness accepted

Decision context

PopulationTreatment-naïve patients and treatment-experienced patients with HIV infection receiving combination antiretroviral therapy

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Nov 2016 Recommended · restricted Truvada® Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile